Efficacy of convalescent plasma for the treatment of COVID-19 in lung transplant recipients: A multicenter French study.

Fiche publication

Date publication

décembre 2024

Journal

Respiratory medicine and research

Auteurs

Membres identifiés du Cancéropôle Est :
Pr FALCOZ Pierre-Emmanuel

Tous les auteurs :
Chaudhry A, Gallais F, Falcoz PE, De Verdiere SC, Villeneuve T, Horeau D, Chatron E, Blanchard E, Collange O, Renaud-Picard B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39689664

Résumé

Lung transplant (LT) recipients are at greater risk of complications from COVID-19. Treatment options are limited partly due to interactions with immunosuppressive agents. Convalescent plasma (CP) is a potential treatment option, but it has not been extensively studied in LT patients. We aimed to assess the efficacy and safety of CP use in France for COVID-19 infected LT patients.